| News

Novartis opens campus up for innovation

17.01.2020

Basel-based pharmaceutical Novartis is opening up its campus in Basel to external partners, including Switzerland Innovation Park Basel Area, which will establish an additional office there.

Novartis opens its campus. The first partner is Switzerland Innovation Park Basel Area
Building on the Novartis Campus into which the Switzerland Innovation Park Basel Area is moving (Photo: Zehnder/Novartis)

The Novartis Campus in Basel is a “city within a city”, according to an article by the Swiss broadcasting company SRF. Some 9,500 people currently work there, and the campus features restaurants and stores.

In the future, external firms and institutions will also find a home on the campus after the Basel-based pharmaceutical decided to open its campus to others.

“In today’s digital world, information can no longer be protected by fences. Everyone has access to everything from anywhere,” said Jörg Reinhardt, chairman of the board of directors of Novartis.

The first partner to benefit from this move is Switzerland Innovation Park Basel Area, which is operated by the business promotion area BaselArea.swiss. The innovation park will open an additional office on the Novartis Company in April, where it will establish an ideation lab on an area of 500 square meters.  The new lab will offer space for startups to collaborate with Novartis on innovation.

Christof Klöpper, CEO of the Switzerland Innovation Park Basel Area, said in the television programme “Schweiz aktuell“: “For us it is a unique opportunity to be present on the Novartis Campus.  With the additional site of the Switzerland Innovation Park Basel Area we want to give startups, academic groups and companies access to Novartis researchers.  On the Campus we will create an ideation lab to promote innovation.”

A second partner ov Novartis has already been found in the Friedrich Miescher Institute (FMI), which will move into the Novartis Campus in 2023. The building is still under construction.

Novartis also plans to build a new visitor center on the site at a cost of CHF 20 million, which will feature an exhibition about the pharmaceutical company as well as space for hosting events. “We will explain, for instance, how a drug is developed or what gene therapy is,” Reinhardt explained.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
TargImmune raises nearly 18 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

TargImmune raises nearly 18 million Swiss francs

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends...

Read More
KetoSwiss launches first product in the USA
Basel Area Business & Innovation, Innovation, Invest

KetoSwiss launches first product in the USA

The Basel-based biotech startup KetoSwiss develops innovative therapies for neurological disorders. Following a successful capital increase, the company now has...

Read More
For Swiss startups, China might be closer than it seems
Basel Area Business & Innovation, Invest

For Swiss startups, China might be closer than it seems

China wants to strengthen domestic demand and be less dependent on imports. This policy has huge implications for the life...

Read More
Basel Area treads unique path
Basel Area Business & Innovation, Innovation, Invest

Basel Area treads unique path

Basel Area is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful...

Read More
Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
1 2 3 46

Do you have a question? We'd like to hear from you.